Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Lasmiditan (Reyvow) is indicated for the acute treatment of migraine with or without aura in adults. It has demonstrated a higher probability of achieving pain freedom within 2 hours compared to Ubrogepant and Zavegepant, particularly at doses of 100 mg and 200 mg.
• Fifteen systematic reviews/meta-analyses on the use of Reyvow (lasmiditan) for the acute treatment of migraine in adults were reviewed.
• Compared to other drugs such as Rimegepant and Ubrogepant, Lasmiditan showed variable efficacy when compared with traditional triptans, which often displayed higher odds ratios for pain freedom at two hours.
• However, Lasmiditan was associated with a greater risk of adverse effects, predominantly central nervous system-related events like dizziness, somnolence, fatigue, paresthesia, and nausea. This contrasted with better tolerability profiles observed from using Ubrogepant or calcitonin gene-related peptide antagonists like Rimegepant and Zavegepant that posed lower risks for these CNS effects.
• The choice between dosages involves balancing increased efficacy against risk factors; while the higher dose consistently showed greater effectiveness in achieving pain relief but also heightened risk reactions.
• Lasmiditan's mechanism as a serotonin receptor agonist offers a potential advantage for those having cardiovascular concerns despite its high incidence rate towards CNS-related side-effects.
• While it is effective especially among those needing rapid relief or have cardiovascular issues, its profile necessitates careful assessment based on patient-specific factors due to its adverse effect profile requiring dose optimization based on individual response tolerance levels.
• The comparative efficacy-safety balance offered by Lasmiditan might be preferential among certain subgroups such as those having specific cardiovascular risks, making understanding nuances crucial towards optimizing management strategies.